Export this Abstract | Print this Abstract | Add to my preferred Abstracts list | My preferred Abstracts list (0) | Back to Search
The safety of febuxostat versus allopurinol in gout patients with hyperuricemia.
- At: 2017 FIP Congress in Seoul (South Korea)
- Type: Poster
- By: CHEN, Jungyi (Kaohsiung Veterans General Hospital, Tainan City, China Taiwan)
- Co-author(s): Jungyi Chen
BackgroundThe efficacy of Febuxostat is as effective as or more effective than Allopurinol in several evidences. However, FDA had warned that Febuxostat may produce fatal or nonfatal liver failure on November 2012, but the evidence about abnormal liver function was controversial till now.
To evaluate the safety of Febuxostat included all.. The access to the whole abstract and the presentation file is available to FIP members and to congress participants of that specific congress.
Last update 4 October 2019